



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2010	2009	% Change			2010	2009	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)</sup></b>										
<b>SKIN CARE</b>										
US	352	378	-6.9%	-6.9%	-	1,537	1,582	-2.8%	-2.8%	-
Intl	537	572	-6.1%	-5.5%	-0.6%	1,915	1,885	1.6%	-0.3%	1.9%
WW	889	950	-6.4%	-6.1%	-0.3%	3,452	3,467	-0.4%	-1.4%	1.0%
<b>BABY CARE</b>										
US	103	106	-2.8%	-2.8%	-	409	414	-1.2%	-1.2%	-
Intl	474	468	1.3%	1.0%	0.3%	1,800	1,701	5.8%	2.6%	3.2%
WW	577	574	0.5%	0.2%	0.3%	2,209	2,115	4.4%	1.9%	2.5%
<b>ORAL CARE</b>										
US	149	167	-10.8%	-10.8%	-	635	716	-11.3%	-11.3%	-
Intl	240	241	-0.4%	-0.9%	0.5%	891	853	4.5%	0.7%	3.8%
WW	389	408	-4.7%	-5.0%	0.3%	1,526	1,569	-2.7%	-4.8%	2.1%
<b>OTC/NUTRITIONALS</b>										
US	381	807	-52.8%	-52.8%	-	1,853	2,944	-37.1%	-37.1%	-
Intl	711	767	-7.3%	-5.2%	-2.1%	2,696	2,686	0.4%	-0.8%	1.2%
WW	1,092	1,574	-30.6%	-29.6%	-1.0%	4,549	5,630	-19.2%	-19.8%	0.6%
<b>WOMEN'S HEALTH</b>										
US	118	135	-12.6%	-12.6%	-	522	578	-9.7%	-9.7%	-
Intl	332	354	-6.2%	-4.8%	-1.4%	1,322	1,317	0.4%	-1.6%	2.0%
WW	450	489	-8.0%	-7.0%	-1.0%	1,844	1,895	-2.7%	-4.1%	1.4%
<b>WOUND CARE/OTHER</b>										
US	116	119	-2.5%	-2.5%	-	563	603	-6.6%	-6.6%	-
Intl	97	135	-28.1%	-27.4%	-0.7%	447	524	-14.7%	-17.8%	3.1%
WW	213	254	-16.1%	-16.1%	0.0%	1,010	1,127	-10.4%	-11.7%	1.3%
<b>TOTAL CONSUMER</b>										
US	1,219	1,712	-28.8%	-28.8%	-	5,519	6,837	-19.3%	-19.3%	-
Intl	2,391	2,537	-5.8%	-4.9%	-0.9%	9,071	8,966	1.2%	-1.0%	2.2%
WW	3,610	4,249	-15.0%	-14.5%	-0.5%	14,590	15,803	-7.7%	-8.9%	1.2%

See footnotes on last page

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FOURTH QUARTER</b>					<b>TWELVE MONTHS</b>				
	<b>2010</b>	<b>2009</b>	<b>% Change</b>			<b>2010</b>	<b>2009</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>PHARMACEUTICAL SEGMENT <sup>(2) (7)</sup></b>										
<b>ACIPHEX/PARIET</b>										
US	119	158	-24.7%	-24.7%	-	475	555	-14.4%	-14.4%	-
Intl	133	154	-13.6%	-9.8%	-3.8%	531	541	-1.8%	-1.3%	-0.5%
WW	252	312	-19.2%	-17.3%	-1.9%	1,006	1,096	-8.2%	-7.9%	-0.3%
<b>CONCERTA</b>										
US	261	279	-6.5%	-6.5%	-	929	986	-5.8%	-5.8%	-
Intl	107	102	4.9%	5.4%	-0.5%	390	340	14.7%	11.6%	3.1%
WW	368	381	-3.4%	-3.3%	-0.1%	1,319	1,326	-0.5%	-1.3%	0.8%
<b>DURAGESIC/FENTANYL TRANSDERMAL</b>										
US	45	53	-15.1%	-15.1%	-	162	216	-25.0%	-25.0%	-
Intl	151	180	-16.1%	-15.6%	-0.5%	586	672	-12.8%	-14.0%	1.2%
WW	196	233	-15.9%	-15.5%	-0.4%	748	888	-15.8%	-16.7%	0.9%
<b>LEVAQUIN/FLOXIN</b>										
US	386	433	-10.9%	-10.9%	-	1,312	1,478	-11.2%	-11.2%	-
Intl	14	19	-26.3%	-28.4%	2.1%	45	72	-37.5%	-40.1%	2.6%
WW	400	452	-11.5%	-11.6%	0.1%	1,357	1,550	-12.5%	-12.6%	0.1%
<b>PREZISTA</b>										
US	111	88	26.1%	26.1%	-	401	303	32.3%	32.3%	-
Intl	125	91	37.4%	43.9%	-6.5%	456	289	57.8%	59.5%	-1.7%
WW	236	179	31.8%	35.1%	-3.3%	857	592	44.8%	45.7%	-0.9%
<b>PROCRIT/EPREX</b>										
US	270	308	-12.3%	-12.3%	-	1,070	1,258	-14.9%	-14.9%	-
Intl	209	268	-22.0%	-18.4%	-3.6%	864	987	-12.5%	-11.7%	-0.8%
WW	479	576	-16.8%	-15.1%	-1.7%	1,934	2,245	-13.9%	-13.6%	-0.3%
<b>REMICADE</b>										
US	679	758	-10.4%	-10.4%	-	3,099	3,088	0.4%	0.4%	-
US Exports <sup>(3)</sup>	381	375	1.6%	1.6%	-	1,487	1,196	24.3%	24.3%	-
Intl	5	5	0.0%	0.0%	0.0%	24	20	20.0%	19.1%	0.9%
WW	1,065	1,138	-6.4%	-6.4%	0.0%	4,610	4,304	7.1%	7.1%	0.0%
<b>RISPERDAL/RISPERIDONE</b>										
US	2	24	-91.7%	-91.7%	-	(12)	247	-104.9%	-104.9%	-
Intl	149	169	-11.8%	-13.0%	1.2%	539	652	-17.3%	-19.4%	2.1%
WW	151	193	-21.8%	-22.8%	1.0%	527	899	-41.4%	-42.9%	1.5%
<b>RISPERDAL CONSTA</b>										
US	105	133	-21.1%	-21.1%	-	445	519	-14.3%	-14.3%	-
Intl	283	266	6.4%	10.5%	-4.1%	1,055	906	16.4%	17.4%	-1.0%
WW	388	399	-2.8%	-0.1%	-2.7%	1,500	1,425	5.3%	5.9%	-0.6%
<b>TOPAMAX</b>										
US	37	89	-58.4%	-58.4%	-	199	731	-72.8%	-72.8%	-
Intl	84	103	-18.4%	-15.6%	-2.8%	339	420	-19.3%	-19.3%	0.0%
WW	121	192	-37.0%	-35.5%	-1.5%	538	1,151	-53.3%	-53.3%	0.0%
<b>VELCADE</b>										
US	-	-	-	-	-	-	-	0.0%	0.0%	-
Intl	287	281	2.1%	4.1%	-2.0%	1,080	933	15.8%	15.5%	0.3%
WW	287	281	2.1%	4.1%	-2.0%	1,080	933	15.8%	15.5%	0.3%
<b>OTHER <sup>(4)</sup></b>										
US	753	640	17.7%	17.7%	-	2,952	2,464	19.8%	19.8%	-
Intl	1,014	1,017	-0.3%	0.4%	-0.7%	3,968	3,647	8.8%	7.0%	1.8%
WW	1,767	1,657	6.6%	7.0%	-0.4%	6,920	6,111	13.2%	12.1%	1.1%
<b>TOTAL PHARMACEUTICAL</b>										
US	3,149	3,338	-5.7%	-5.7%	-	12,519	13,041	-4.0%	-4.0%	-
Intl	2,561	2,655	-3.5%	-1.6%	-1.9%	9,877	9,479	4.2%	3.4%	0.8%
WW	5,710	5,993	-4.7%	-3.9%	-0.8%	22,396	22,520	-0.6%	-1.0%	0.4%
<b>MAJOR NEW PHARM PRODUCTS <sup>(5)</sup></b>										
<b>INVEGA</b>										
US	70	72	-2.8%	-2.8%	-	270	266	1.5%	1.5%	-
Intl	46	34	35.3%	37.9%	-2.6%	154	127	21.3%	21.3%	0.0%
WW	116	106	9.4%	10.2%	-0.8%	424	393	7.9%	7.9%	0.0%

See footnotes on last page

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FOURTH QUARTER</b>					<b>TWELVE MONTHS</b>				
	<b>2010</b>	<b>2009</b>	<b>% Change</b>			<b>2010</b>	<b>2009</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>MEDICAL DEVICES AND DIAGNOSTICS <sup>(2)</sup></b>										
<b><u>CORDIS <sup>(6)</sup></u></b>										
US	246	240	2.5%	2.5%	-	1,008	971	3.8%	3.8%	-
Intl	383	457	-16.2%	-16.3%	-0.1%	1,544	1,708	-9.6%	-11.3%	1.7%
WW	629	697	-9.8%	-9.9%	0.1%	2,552	2,679	-4.7%	-5.8%	1.1%
<b><u>DEPUY</u></b>										
US	807	828	-2.5%	-2.5%	-	3,145	3,096	1.6%	1.6%	-
Intl	640	645	-0.8%	0.0%	-0.8%	2,440	2,276	7.2%	5.2%	2.0%
WW	1,447	1,473	-1.8%	-1.4%	-0.4%	5,585	5,372	4.0%	3.2%	0.8%
<b><u>DIABETES CARE</u></b>										
US	318	313	1.6%	1.6%	-	1,259	1,221	3.1%	3.1%	-
Intl	326	342	-4.7%	-5.0%	0.3%	1,211	1,219	-0.7%	0.1%	-0.8%
WW	644	655	-1.7%	-1.8%	0.1%	2,470	2,440	1.2%	1.6%	-0.4%
<b><u>ETHICON</u></b>										
US	501	458	9.4%	9.4%	-	2,000	1,754	14.0%	14.0%	-
Intl	651	651	0.0%	0.6%	-0.6%	2,503	2,368	5.7%	4.0%	1.7%
WW	1,152	1,109	3.9%	4.3%	-0.4%	4,503	4,122	9.2%	8.2%	1.0%
<b><u>ETHICON ENDO-SURGERY</u></b>										
US	501	532	-5.8%	-5.8%	-	1,975	1,974	0.1%	0.1%	-
Intl	756	724	4.4%	4.6%	-0.2%	2,783	2,518	10.5%	8.4%	2.1%
WW	1,257	1,256	0.1%	0.2%	-0.1%	4,758	4,492	5.9%	4.7%	1.2%
<b><u>ORTHO-CLINICAL DIAGNOSTICS</u></b>										
US	276	258	7.0%	7.0%	-	1,091	1,104	-1.2%	-1.2%	-
Intl	260	243	7.0%	6.9%	0.1%	962	859	12.0%	9.9%	2.1%
WW	536	501	7.0%	6.9%	0.1%	2,053	1,963	4.6%	3.7%	0.9%
<b><u>VISION CARE</u></b>										
US	212	188	12.8%	12.8%	-	934	891	4.8%	4.8%	-
Intl	447	430	4.0%	0.7%	3.3%	1,746	1,615	8.1%	3.8%	4.3%
WW	659	618	6.6%	4.3%	2.3%	2,680	2,506	6.9%	4.1%	2.8%
<b><u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u></b>										
US	2,861	2,817	1.6%	1.6%	-	11,412	11,011	3.6%	3.6%	-
Intl	3,463	3,492	-0.8%	-1.0%	0.2%	13,189	12,563	5.0%	3.0%	2.0%
WW	6,324	6,309	0.2%	0.1%	0.1%	24,601	23,574	4.4%	3.4%	1.0%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Includes December YTD 2010 sales of \$393MM for STELARA and \$226MM for SIMPONI.

(5) Included in Other

(6) Includes sales of Drug-Eluting Stents for Q4 2010 of \$46, \$88 and \$134MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q4 2009 of \$56, \$167 and \$223MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for December YTD 2010 of \$212, \$415 and \$627MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for December YTD 2009 of \$245, \$674 and \$919MM Domestic, International and Worldwide respectively

(7) Conforms to current presentation